25 March 2020
Botanix announces top line BTX 1204 atopic dermatitis data
• BTX 1204 did not achieve statistical significance in the primary and secondary endpoints in its
Phase 2 atopic dermatitis study
• Botanix will be finalising a comprehensive review of the study data and will provide an update
on the BTX 1204 program and its broader dermatology platform
Philadelphia PA and Sydney Australia, 25 March 2020: Clinical stage synthetic cannabinoid company
Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”) today announced that BTX
1204 did not meet the primary endpoint in its Phase 2 study evaluating the safety and efficacy in
patients with moderate atopic dermatitis (“1204 Study”).
Sad
Ann: Antimicrobial Platform Update and Launch of BTX 1801 Study, page-79
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.015(5.17%) |
Mkt cap ! $433.1M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.0¢ | 27.5¢ | $1.164M | 4.100M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 534239 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 77302 | 2 |
View Market Depth
| Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
28.0¢ |
Change
-0.015 ( 2.61 %) |
||||
| Open | High | Low | Volume | ||
| 28.5¢ | 29.0¢ | 27.5¢ | 2348390 | ||
| Last updated 15.59pm 28/05/2024 ? | |||||
| BOT (ASX) Chart |